Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement

Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash Combination Provides Expertise and Resources to Address Unmet Patient Needs in Women’s Health and Prostate Cancer Agreement Unanimously Recommended by Special Committee of Myovant’s Independent Directors and Approved by Board NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 /PRNewswire/ — Sumitovant Biopharma Ltd. (“Sumitovant”), in conjunction with […]

Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022

July 27, 2022 at 4:05 PM EDT First fiscal quarter 2022 total revenue of $116.5 million, including net product revenue of $41.4 million Net product revenue from U.S. sales of ORGOVYX® of $36.0 million in first fiscal quarter 2022, with sequential quarterly demand volume growth of 26% and cumulative patients estimated at 18,000 through June 2022 Net product revenue from U.S. sales of MYFEMBREE® of $4.0 million in […]

Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 2 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women with Endometriosis-Associated Pain

June 17, 2022 at 6:45 AM EDT BASEL, Switzerland and NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that results of the Phase 3 SPIRIT 1 and SPIRIT 2 studies of investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in over 1,200 women […]

Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®

June 2, 2022 at 6:50 AM EDT BASEL, Switzerland and NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg). The sNDA proposes updates to MYFEMBREE’s […]

Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022

May 10, 2022 at 6:55 AM EDT Fiscal year 2021 total revenue of $231.0 million, including net product revenues of $94.3 million; fourth fiscal quarter 2021 total revenues of $57.6 million, including net product revenue of $32.4 million European Commission approval of ORGOVYX® as the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in Europe in April 2022 Announced exclusive […]

Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe

May 9, 2022 at 6:30 AM EDT Myovant to receive an upfront payment of $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to $90.5 million Myovant also eligible to receive tiered royalties from the high-teens to mid-twenties on net sales BASEL, Switzerland and HARROW, United Kingdom, May 09, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Accord Healthcare, […]

Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer

April 29, 2022 at 7:10 PM EDT ORGOVYX® is the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in Europe Myovant expects to secure European commercialization partner ahead of anticipated launches BASEL, Switzerland, April 29, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) today announced that the European Commission (EC) has approved the marketing authorisation application for ORGOVYX® (relugolix, 120 mg) for the treatment of adult patients with advanced hormone-sensitive prostate cancer. The […]

Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer

February 25, 2022 CHMP opinion recommending approval based on data from the global Phase 3 HERO study If approved, ORGOVYX® would be the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in Europe Company remains on track to reach agreement with a partner for international rights to relugolix in oncology by […]

Myovant Sciences to Present at Upcoming Investor Conferences

BASEL, Switzerland, Feb. 07, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., and other members of the Myovant executive team will participate in a fireside chat at the following investor conferences: 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022, […]

Myovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates

January 26, 2022 at 6:55 AM ESTPDF Version Third fiscal quarter 2021 total revenues of $54.4 million, including net product revenue of $29.3 million Net product revenue from U.S. sales of ORGOVYX® of $24.4 million, reflecting 40% sequential volume growth compared to second fiscal quarter 2021, partially offset by a lower net price Net product revenue from U.S. sales of MYFEMBREE® of $2.4 million; New-to-brand […]